2. Search Result
Search Result
Results for "

breast and prostate cancers

" in MedChemExpress (MCE) Product Catalog:

46

Inhibitors & Agonists

1

Screening Libraries

1

Biochemical Assay Reagents

5

Peptides

9

Natural
Products

1

Isotope-Labeled Compounds

1

Click Chemistry

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N10361
    Drupanin

    		RAR/RXR PPAR Cancer
    Drupanin is an orally active selective AKR1C3 enzyme inhibitor and an RXRα agonist with an EC50 value of 4.8 μM, which is isolated from green propolis. Drupanin also activates PPARγ moderately. Drupanin induces adipogenesis and elevates aP2 mRNA levels in 3T3-L1 fibroblasts Drupanin has the potential for the research of breast and prostate cancers .
    Drupanin
  • HY-148761
    PSMA I&T

    		PSMA Cancer
    PSMA I&T is an effective inhibitor of prostate-specific membrane antigen (PSMA). PSMA I&T can be used for SPECT/CT imaging and radionuclide studies in triple-negative breast cancer and prostate cancer (PCa) .
    PSMA I&T
  • HY-13673A
    Goserelin acetate

    ICI-118630 acetate

    		 GnRH Receptor Apoptosis Endocrinology Cancer
    Goserelin acetate (ICI-118630 acetate), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin acetate can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .
    Goserelin acetate
  • HY-N3755
    Dihydroresveratrol

    		Estrogen Receptor/ERR Cancer
    Dihydroresveratrol, a potent phytoestrogen, is a hormone receptor modulator. Dihydroresveratrol exhibits proliferative effects in androgen-independent prostate and breast cancer cells at picomolar and nanomolar concentrations .
    Dihydroresveratrol
  • HY-N2059
    Santalol

    		Others Cancer
    Santalol is a mixture of α and β-isomer santalol. α-santalol is isolated from sandalwood oil. α-santalol is a promising anti-cancer agent against cancers such as oral, breast, prostate and skin cancer .
    Santalol
  • HY-114988
    PGE-M

    tetranor-PGEM

    		 Endogenous Metabolite Inflammation/Immunology Cancer
    PGE-M is a metabolite of prostaglandin E2 (PEG2) as a biomarker of inflammation and cancer including advanced colorectal neoplasia, ovarian cancer, prostate cancer and so on. Urinary PGE-M is positively associated with obesity, smoking and lung metastases with breast cancer .
    PGE-M
  • HY-14281
    Trilostane
    2 Publications Verification

    Win 24540

    		 Others Endocrinology Cancer
    Trilostane (Win 24540) is a competitive and orally active 3-β-hydroxysteroiddehydrogenase (3β-HSD) inhibitor. Trilostane is a synthetic nonhormonal steroid. Trilostane can be used for the research of breast cancer and prostate cancer .
    Trilostane
  • HY-158251
    BIBD-300

    		Others Cancer
    BIBD-300 is a PARP-1 imaging agent with high affinity for PARP-1. BIBD-300 can accurately localize C6 and U87MG tumors, which can be used for research in the diagnosis of breast cancer, prostate cancer, glioma, and liver cancer .
    BIBD-300
  • HY-13673
    Goserelin

    ICI 118630

    		 GnRH Receptor Apoptosis Endocrinology Cancer
    Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .
    Goserelin
  • HY-P4144
    Onvitrelin ucalontide

    Phor18-LHRH (338613)

    		 GnRH Receptor Endocrinology Cancer
    Onvitrelin ucalontide ([Phor18-LHRH (338613)]) is an analogue of luteinizing hormone releasing hormone (LHRH) with antineoplastic activity. Onvitrelin ucalontide is a peptide with sequences of KFAKFAKKFAKFAKKFAKQHWSYGLRPG. Onvitrelin ucalontide effectively inhibits breast cancer, ovarian cancer and prostate cancer xenografts in mouse model .
    Onvitrelin ucalontide
  • HY-116904
    Anticancer agent 253

    		Apoptosis Akt Cancer
    Anticancer agent 253 (Compound 26) has anti-cancer activity against breast cancer cells, with IC50s of 6 μM (MCF-7), 10 μM (MDA-MB-231) and 6.4 μM (4T1 cells). Anticancer agent 253 arrests cell cycle and induces mitochondria-mediated apoptosis in cancer cells. Anticancer agent 253 inhibits Akt phosphorylation in human breast and prostate cancer .
    Anticancer agent 253
  • HY-N1252
    Scillascillin

    		Others Cancer
    Scillascillin (compound 10) is a homoisoflavanone. Scillascillin can be isolated from S. scilloides. Scillascillin shows anticancer activity towards MCF-7 (breast cancer) and DU-145 (prostate cancer) cells with the IC50 of 9.59 and 11.32 ug/ml, respectively .
    Scillascillin
  • HY-146433
    Anticancer agent 55

    		Apoptosis Cancer
    Anticancer agent 55 is a potent anticancer agent. Anticancer agent 55 shows anticancer activity via reducing the cell viability and cell migration in a dose-dependent manner. Anticancer agent 55 induces apoptosis. Anticancer agent 55 has the potential for the research of prostate cancer and breast cancer .
    Anticancer agent 55
  • HY-14281R
    Trilostane (Standard)

    		Others Endocrinology Cancer
    Trilostane (Standard) is the analytical standard of Trilostane. This product is intended for research and analytical applications. Trilostane (Win 24540) is a competitive and orally active 3-β-hydroxysteroiddehydrogenase (3β-HSD) inhibitor. Trilostane is a synthetic nonhormonal steroid. Trilostane can be used for the research of breast cancer and prostate cancer .
    Trilostane (Standard)
  • HY-156419
    PARP7-IN-16

    		PARP Cancer
    PARP7-IN-16 (compound 36) is a potent, selective and orally active inhibitor of PARP-1/2/7, with IC50s of 0.94, 0.87 and 0.21 nM, respectively. PARP7-IN-16 can be used for the research of breast cancer and prostate cancer .
    PARP7-IN-16
  • HY-119694
    Rotenolone

    		Others Cancer
    Rotenolone is an antiproliferative agent. Rotenolone shows antiproliferative activity against the ovarian cancer A2780, breast cancer BT-549, prostate cancer DU 145, NSCLC NCI-H460, and colon cancer HCC-2998 cell lines, with IC50s of 0.95, 1.6, 2.7, 2.0, and 2.9 μM, respectively .
    Rotenolone
  • HY-125010
    Dicycloplatin

    		DNA/RNA Synthesis Apoptosis Cancer
    Dicycloplatin is a DNA damage inducer. Dicycloplatin induces DNA damage by activating biphosphorylated checkpoint kinase 2 (CHK2), breast cancer 1 (BRCA1) and triphosphorylated p53. Dicycloplatin can induce cell cycle arrest, inhibit proliferation and lead to apoptosis in prostate cancer PC3 cells and lung cancer NCI/H446 cells. Dicycloplatin can be used in cancer researchr .
    Dicycloplatin
  • HY-P10511
    Pantinin-3

    		Apoptosis Infection Cancer
    Pantinin-3 is an antimicrobial peptide with antitumor activity found in the venom of the emperor scorpion (Pandinus imperator). Pantinin-3 shows selective toxicity against breast cancer cells (MDA-MB-231) and prostate cancer cells (DU-145). Pantinin-3 can induce apoptosis in tumor cells. Pantinin-3 can be used in cancer research .
    Pantinin-3
  • HY-103367
    CHK1-IN-7

    		Checkpoint Kinase (Chk) Cancer
    CHK1-IN-7 (Compound 10c) is a potent human CHK1 inhibitor. CHK1-IN-7 shows no single agent effect, potentiates the antiproliferative effect of Gemcitabine HY-17026 in both prostate and breast cancer cell lines. CHK1-IN-7 can be used for the research of cancer .
    CHK1-IN-7
  • HY-143247
    Tubulin polymerization-IN-2

    		Microtubule/Tubulin Cancer
    Tubulin polymerization-IN-2 is a potent anticancer agent targeting to β-tubulin with an IC50 value of 0.92 μM. Tubulin polymerization-IN-2 shows promising activity against various leukemia, non-small lung, renal, prostate, and breast cancer cell lines .
    Tubulin polymerization-IN-2
  • HY-106056
    Zindoxifene

    D 16726

    		 Others Cancer
    Zindoxifene is a partial anti-estrogen. Zindoxifene works primarily by binding to estrogen receptors, thereby inhibiting the growth of estrogen-dependent tumor cells. Zindoxifene is able to exhibit the dual properties of estrogen agonists and antagonists and can be used in research and development to target estrogen-dependent tumors, such as prostate and breast cancer .
    Zindoxifene
  • HY-149894
    MC-1-F2

    		Biochemical Assay Reagents Cancer
    MC-1-F2 is a FOXC2 inhibitor that reduces epithelial-mesenchymal transition (EMT) markers in breast cancer cells, suppresses cancer stem cell (CSC) properties and reduces invasiveness in castration-resistant prostate cancer (CRPC) cells. There is a synergistic effect between MC-1-F2 and Docetaxel, which has the potential to be used in combination to study CRPC .
    MC-1-F2
  • HY-153910
    AGPS-IN-1

    		Others Cancer
    AGPS-IN-1 (Compound 2i) is an effective AGPS binder. AGPS-IN-1 reduces ether lipids levels and cell migration rate. AGPS-IN-1 inhibits epithelial-mesenchymal transition (EMT) in prostate PC-3 and breast MDA-MB-231 cancer cells .
    AGPS-IN-1
  • HY-14281S
    Trilostane-d3

    Win 24540-d3

    		 Isotope-Labeled Compounds Others
    Trilostane-d3 is the deuterium-labeled Trilostane (HY-14281). Trilostane-d3 (Win 24540) is a competitive and orally active 3-β-hydroxysteroiddehydrogenase (3β-HSD) inhibitor. Trilostane-d3 is a synthetic nonhormonal steroid. Trilostane-d3 can be used for the research of breast cancer and prostate cancer .
    Trilostane-d3
  • HY-147081
    AS 1411

    AGRO-100

    		 Histone Methyltransferase Bcl-2 Family Cancer
    AS 1411 (AGRO-100) is an oligonucleotide aptamer targeting nucleoproteins. AS 1411 inhibits tumor cell proliferation by affecting the activity of nucleoprotein-containing complexes and can be used as a carrier to precisely deliver nanoparticles, oligonucleotides and small molecules to cancer cells. AS 1411 reduces PRMT5 expression to inhibit tumor growth in DU145 prostate cancer cells. AS 1411 works by blocking the binding of nucleoproteins to bcl-2 mRNA in MCF-7 breast cancer cells. AS 1411-coupled Jin nanospheres can inhibit breast cancer cell proliferation in vitro and in mouse models, has the ability to cross the blood-brain barrier with low tissue toxicity .
    AS 1411
  • HY-146230
    VEGFR-2-IN-26

    		VEGFR Cancer
    VEGFR-2-IN-26 (compound 5h) is a highly potent VEGFR-2 inhibitor with an IC50 value of 15.5 nM. VEGFR-2-IN-26 has good antiproliferative activity against the leukemic, non-small lung, CNS, ovarian, renal, prostate and breast cancer cells .
    VEGFR-2-IN-26
  • HY-107408
    SANT 2

    		Hedgehog Cancer
    SANT 2 is a potent antagonist of Hh-signaling pathway. Hedgehog (Hh) signaling plays an important role in cell signaling of embryonic development and adult tissue homeostasis. SANT 2 has the potential for the research of several malignancies including Gorlin syndrome (a disorder predisposing to basal cell carcinoma, medulloblastoma and rhabdomyosarcoma), prostate, pancreatic and breast cancers .
    SANT 2
  • HY-163938
    PROTAC erf3a Degrader-1

    		PROTACs Cancer
    PROTAC erf3a Degrader-1 (Compound C63) is an orally active PROTAC erf3a Degrader. PROTAC erf3a Degrader-1 inhibits cancer cell proliferation (eg: 22Rv1). PROTAC erf3a Degrader-1 can be used for research of prostate cancer, ovarian cancer, liver cancer, cervical cancer, leukemia, breast cancer. (Red: erf3a ligand (HY-13778); Black: linker (HY-163960); Blue: CRBN ligand (HY-41547)) .
    PROTAC erf3a Degrader-1
  • HY-152479
    Topoisomerase IIα-IN-7

    		Topoisomerase Cancer
    Topoisomerase IIα-IN-7 is an DNA topoisomerase IIα inhibitor with an IC50 value of 7.7 µM. Topoisomerase IIα-IN-7 has broad-spectrum cytotoxicity to leukemia, lung, colon, melanoma, ovarian, kidney, prostate and breast cancer cells. Topoisomerase IIα-IN-7 has metabolic stability .
    Topoisomerase IIα-IN-7
  • HY-155458
    HYDAMTIQ

    		PARP Inflammation/Immunology Cancer
    HYDAMTIQ is a PARP-1/2 inhibitor (IC50: 29-38 nM) with anticancer, anti-inflammatory, and ischemic protective effects. HYDAMTIQ inhibits pulmonary PARP activity, is effective against allergen-induced cough and dyspnea, and inhibits bronchial hyperresponsiveness to methacholine. HYDAMTIQ has broad-spectrum tumor suppressor effects, including ovarian and breast cancers, prostate and pancreatic tumors, and glioblastoma multiforme. HYDAMTIQ has demonstrated in vivo efficacy in animal models of cerebral ischemia, asthma, cancer, and more .
    HYDAMTIQ
  • HY-156419A
    PARP7-IN-16 free base

    		PARP Cancer
    PARP7-IN-16 free base is the free base form of PARP7-IN-16 (HY-156419). PARP7-IN-16 free base is a selective and orally active inhibitor of PARP-1/2/7, with IC50s of 0.94, 0.87 and 0.21 nM, respectively. PARP7-IN-16 can be used for the research of breast cancer and prostate cancer .
    PARP7-IN-16 free base
  • HY-158328A
    CA IX/VEGFR-2-IN-2

    		Carbonic Anhydrase VEGFR Reactive Oxygen Species MDM-2/p53 Bcl-2 Family Cytochrome P450 Caspase Cancer
    CA IX/VEGFR-2-IN-2 (compound 5e) is a dual-targeted inhibitor. CA IX/VEGFR-2-IN-2 shows strong inhibitory effects on both CA IX (Ki=3.1 μM) and VEGFR-2 (IC50=32.1 nM). CA IX/VEGFR-2-IN-2 can be used for the study of pancreatic (PANC1), breast cancer (MCF7) and prostate cancer (PC3) .
    CA IX/VEGFR-2-IN-2
  • HY-144059
    AKT-IN-9

    		Akt Cancer
    AKT-IN-9 is a potent inhibitor of AKT. Protein kinase B (PKB, also known as AKT) is central to PI3K/AKT/mTOR signaling in cells, and its function is important for cell growth, survival, differentiation and metabolism. AKT-IN-9 has the potential for the research of breast and prostate cancer (extracted from patent WO2021185238A1, compound 1) .
    AKT-IN-9
  • HY-144060
    AKT-IN-10

    		Akt Cancer
    AKT-IN-10 is a potent inhibitor of AKT. Protein kinase B (PKB, also known as AKT) is central to PI3K/AKT/mTOR signaling in cells, and its function is important for cell growth, survival, differentiation and metabolism. AKT-IN-10 has the potential for the research of breast and prostate cancer (extracted from patent WO2021185238A1, compound 4) .
    AKT-IN-10
  • HY-144094
    EZH2-IN-9

    		Histone Methyltransferase Cancer
    EZH2-IN-9 is a potent inhibitor of EZH2. EZH2 overexpression or mutations in the SET region (Y641F, Y641N, A687V, A677G point mutations) all lead to abnormal elevation of H3K27me3 and promote the growth and development of many types of tumors, such as breast cancer, prostate cancer, leukemia, etc. EZH2-IN-9 has the potential for the research of cancer diseases (extracted from patent WO2021180235A1, compound 17) .
    EZH2-IN-9
  • HY-143616
    EZH2-IN-7

    		Histone Methyltransferase Cancer
    EZH2-IN-7 is a potent inhibitor of EZH2. EZH2 overexpression or mutations in the SET region (Y641F, Y641N, A687V, A677G point mutations) all lead to abnormal elevation of H3K27me3 and promote the growth and development of many types of tumors, such as breast cancer, prostate cancer, leukemia, etc. EZH2-IN-7 has the potential for the research of cancer diseases (extracted from patent WO2021129629A1, compound 259) .
    EZH2-IN-7
  • HY-N6796
    Manumycin A

    		Farnesyl Transferase Ras Apoptosis Phospholipase TNF Receptor Atg8/LC3 Infection Inflammation/Immunology Cancer
    Manumycin A is a polyketide antibiotic and an inhibitor of thioredoxin reductase 1 (TrxR-1). Manumycin A can inhibit the growth of breast cancer cells and exert its anti-tumor activity through LC3. Manumycin A can downregulate the release of pro-inflammatory cytokines in human monocytes stimulated by TNF α, and has potential anti-inflammatory activity. Manumycin A can inhibit the Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration resistant prostate cancer cells to suppress exosome biogenesis and secretion .
    Manumycin A
  • HY-163938A
    PROTAC erf3a Degrader-2

    		PROTACs Cancer
    PROTAC erf3a Degrader-2 (Compound C59) is an orally active PROTAC erf3a Degrader. PROTAC erf3a Degrader-2 inhibits protein expression of SRD5A3 and GSPT1(eRF3a). PROTAC erf3a Degrader-2 inhibits cancer cell proliferation (eg: 22Rv1). PROTAC erf3a Degrader-2 can be used for research of prostate cancer, ovarian cancer, liver cancer, cervical cancer, leukemia, breast cancer. (Red: erf3a ligand (HY-13778); Black: linker (HY-163960); Blue: E3 ligase ligand (HY-W763812)) .
    PROTAC erf3a Degrader-2
  • HY-N12606
    Neodidymelliosides A

    		Fungal Infection
    Neodidymelliosides A (compound 1)It is a secondary metabolite of fungi and has a significant inhibitory effect on Staphylococcus aureus and Candida albicans biofilms. Neodidymelliosides AIt also has anti-cancer activity and can inhibit KB3.1 (cervix),PC-3 (prostate),MCF-7(breast),SKOV-3 (ovary),A431 (skin )and A549 (lung )Cell viability of cell lines .
    Neodidymelliosides A
  • HY-104040
    MKC8866
    Maximum Cited Publications
    8 Publications Verification

    Orin1001

    		 IRE1 Cancer
    MKC8866, a salicylaldehyde analog, is a potent, selective IRE1 RNase inhibitor with an IC50 of 0.29 μM in human vitro. MKC8866 strongly inhibits Dithiothreitol-induced X-box-binding protein 1-spliced (XBP1s) expression with an EC50 of 0.52 μM and unstresses RPMI 8226 cells with an IC50 of 0.14 μM . MKC8866 inhibits IRE1 RNase in breast cancer cells leading to the decreased production of pro-tumorigenic factors and it can inhibits prostate cancer (PCa) tumor growth .
    MKC8866
  • HY-123715
    Anticancer agent 255

    		Others Cancer
    Anticancer agent 255 is a monocarbonylated curcumin-1,2,3-oxazole conjugate with significant anticancer activity. The IC50 values of Anticancer agent 255 in prostate cancer cells PC-3 and DU-145 are 8.8μM and 9.5μM respectively. The IC50 values of Anticancer agent 255 against breast cancer cells MCF-7, MDA-MB-231 and 4T1 are 6μM, 10μM and 6.4μM, showing good anti-cancer activity Effect. Anticancer agent 255 can induce mitochondria-mediated apoptosis in cancer cells and prevent cell cycle progression. Anticancer agent 255 down-regulated the cell proliferation marker PCNA and inhibited the activation of cell survival proteins. Anticancer agent 255 up-regulated the pro-apoptotic protein Bax and down-regulated the anti-apoptotic protein Bcl-2 .
    Anticancer agent 255
  • HY-139090
    3-Oxobetulin acetate

    28-O-Acetyl-3-Oxobetulin; 3-oxo-28-O-Acetylbetulin

    		 Others Infection
    3-Oxobetulin acetate is a derivative of the cholesterol biosynthesis inhibitor Betulin (HY-N0083). It inhibits the growth of P388 murine lymphocytic leukemia cells (EC50=0.12 μg/mL), as well as human MCF-7 breast, SF-268 CNS, H460 lung, and KM20L2 colon cancer cells (GI50s=8, 10.6, 5.2, and 12.7 μg/mL, respectively), but not BxPC-3 pancreas or DU145 prostate cancer cells (GI50s=>10 μg/mL for both).2 3-Oxobetulin acetate inhibits replication of X4 tropic recombinant HIV (NL4.3-Ren) in MT-2 lymphoblastoid cells (IC50=13.4 μM). It is also active against L. donovani amastigotes when used at a concentration of 50 μM.
    3-Oxobetulin acetate
  • HY-117085
    Lobaric acid

    		Others Cancer
    Lobaric acid is a depsidone metabolite that has been isolated from Stereocaulon lichen species with antioxidant, antiproliferative, antiviral, and enzyme inhibitory activites. It scavenges superoxide radicals in a cell-free assay (IC50=97.9 μmol) and inhibits proliferation in a panel of leukemia, colorectal, gastric, breast, ovarian, prostate, pancreatic, and lung cancer cell lines (EC50s=15.2-63.9 μg/ml). Lobaric acid inhibits protein tyrosine phosphatase 1B (PTP1B; IC50=0.87 μM for the human recombinant enzyme) and production of 12(S)-HETE by 12(S)-lipoxygenase (IC50=28.5 μM).In vivo, lobaric acid (250 μM) decreases lesion number, but not lesion diameter, in tobacco leaves infected with tobacco mosaic virus (TMV).
    Lobaric acid
  • HY-N0171
    Beta-Sitosterol (purity>80%)
    5+ Cited Publications

    		 Apoptosis Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology Cancer
    Beta-Sitosterol (purity>80%) includes β-sitosterol (≥80%), stigmasterol, campesterol and brassicasterol mainly. Beta-Sitosterol is a plant sterol. Beta-Sitosterol (purity>80%) interfere with multiple cell signaling pathways, including cell cycle, apoptosis, proliferation, survival, invasion, angiogenesis, metastasis and inflammation .
    Beta-Sitosterol (purity>80%)
  • HY-N0171A
    Beta-Sitosterol (purity>98%)
    5+ Cited Publications

    β-Sitosterol (purity>98%); 22,23-Dihydrostigmasterol (purity>98%)

    		 Apoptosis Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology Cancer
    Beta-Sitosterol (purity>98%) is a plant sterol. Beta-Sitosterol (purity>98%) interfere with multiple cell signaling pathways, including cell cycle, apoptosis, proliferation, survival, invasion, angiogenesis, metastasis and inflammation .
    Beta-Sitosterol (purity>98%)
  • HY-131384
    8,11,14-Eicosatriynoic acid

    8,11,14-Icosatriynoic acid

    		 COX Others
    8,11,14-Eicosatriynoic Acid, as an inhibitor of prostaglandin, leukotriene biosynthesis, and arachidonic acid-induced platelet aggregation, blocks human 12-lipoxygenase (12-LO), cyclooxygenase (COX)and 5-lipoxygenase (5-LO) with IC50 values of 0.46 μM, 14 μMand 25 μM, respectively. In addition, 8,11,14-Eicosatriynoic Acid inhibits the action of slow-reacting substances of allergic reactions, with IC50 value of 10 μM. Lipoxygenase is widely found in fungi, plants and animals. 12-LO involves in many important disease states and may play a role in oxidative glutamate toxicity. COX enzymes play complex roles in human physiology and pathology involving the neuronal, immune, renal, cardiovascular, gastrointestinal and reproductive systems. COX enzymes are blocked by aspirin and a variety of other NSAIDs, which makes them clinically important. 5-LO involves in cancer pathology. It is expressed by a variety of cancer cells, including colon, lung, breast, and prostate cancers, and promotes cancer cell growth and neovascularization . 8,11,14-Eicosatriynoic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    8,11,14-Eicosatriynoic acid

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: